The United States Patent and Trademark Office gave MetP Pharma US Patent treating Demyelinating, as well as, Neuroinflammatory Diseases

An announcement was made recently by MetP Pharma AG that it has been given a Notice of Allowance from the US Patent and Trademark Office for its patent titled as ‘Treatment of Demyelinating Diseases.’

The patent will be valid until the end of 2039 and will be addressing a method for the treatment of demyelinating diseases like amyotrophic lateral sclerosis, multiple sclerosis, as well as, various other diseases in which n....